Literature DB >> 16467002

The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.

Catherine Van Poznak1.   

Abstract

Osteonecrosis of the jaw (ONJ) has been noted to occur in patients with cancer receiving bisphosphonate therapy and may also be referred to as bisphosphonate associated osteonecrosis (BON). ONJ has come to attention through case reporting and the pathogenesis and true incidence of this condition are not yet defined. ONJ appears to be a relatively uncommon event, but it is of clinical significance; the evolving data on ONJ are discussed here.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16467002     DOI： 10.1080/07357900500449652

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  6 in total

1.  Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Authors:  Sebastian Hoefert; Inge Schmitz; Andrea Tannapfel; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2009-06-18       Impact factor: 3.573

2.  Making a case for defining osteonecrosis of the jaw.

Authors:  C Van Poznak
Journal:  J Dent Res       Date:  2011-02-11       Impact factor: 6.116

Review 3.  Osteochemonecrosis: an overview.

Authors:  John Hellstein
Journal:  Head Neck Pathol       Date:  2014-11-20

4.  Osteonecrosis of the jaw and bevacizumab therapy.

Authors:  Catherine Van Poznak
Journal:  Breast Cancer Res Treat       Date:  2010-05-13       Impact factor: 4.872

Review 5.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

6.  Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer.

Authors:  Catherine Van Poznak; Evan L Reynolds; Cherry L Estilo; Mimi Hu; Bryan Paul Schneider; Daniel L Hertz; Christina Gersch; Jacklyn Thibert; Dafydd Thomas; Mousumi Banerjee; James M Rae; Daniel F Hayes
Journal:  Oral Dis       Date:  2020-12-14       Impact factor: 3.511
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.